[Collaboration News] GENECAST Partners with MediCheck, Korea's Largest Health Screening Institution, for Early Cancer Detection

GENECAST has officially embarked on research focused on early lung cancer detection in collaboration with Korea’s largest health screening institution.

On October 28, GENECAST signed a Memorandum of Understanding (MOU) with MediCheck, the research arm of the Korean Association of Health Promotion, Korea’s largest and oldest health screening organization. This MOU emphasizes mutual cooperation for the early detection of cancer through ctDNA liquid biopsy.

Initially, both institutions plan to validate the efficacy of combining ctDNA testing with low-dose CT (LDCT) for early detection in high-risk groups for lung cancer. As the research progresses, they aim to expand the scope of the study and explore commercialization opportunities for early detection of lung and pancreatic cancers via liquid biopsy based on the study's findings.

The first phase of this joint research will be a clinical study to assess the effectiveness of early detection. This study targets high-risk individuals with nodules of a certain size visible on LDCT, aiming to detect key lung cancer gene mutations such as EGFR and KRAS.